Skip to main content

Oncternal Therapeutics Inc Value Stock - Dividend - Research Selection

Gtx inc

ISIN: US68236P1075 , WKN: A2PL3P

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company\'s lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Oncternal Therapeutics: A Buy Rating on Strong Financials and Promising Catalysts

2024-05-13
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Oncternal Therapeutics price target lowered by $9 at H.C. Wainwright, here's why

2024-05-13
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

2024-05-09
Fourth dosing cohort at 300 mg per day is fully enrolled for the Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitors; initial data readout expected in the latter part of the second quarterPhase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for patients with relapsed or refractory aggressive B-cell lymphoma, including patients th

Oncternal Therapeutics, Inc. (ONCT) Q1 2024 Earnings Call Transcript

2024-05-09
Oncternal Therapeutics, Inc. (NASDAQ:NASDAQ:ONCT) Q1 2024 Earnings Call Transcript May 9, 2024 5:00 PM ETCompany ParticipantsRichard Vincent - CFODr.

Oncternal Therapeutics: Q1 Earnings Snapshot

2024-05-09
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q1 2024

2024-05-09
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Oncternal Therapeutics GAAP EPS of -$2.83 beats by $0.05, revenue of $0.57M beats by $0.44M

2024-05-09
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Oncternal Therapeutics reports Q1 EPS ($2.83), consensus ($2.88)

2024-05-09
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Notable earnings after Thursday's close

2024-05-08
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results

2024-05-02
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2024 financial results after the U.S. financial markets close on Thursday, May 9, 2024. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company’s financial results. The live webcast of the ca